Sunsai Laboratories Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 05-12-2024
- Paid Up Capital ₹ 0.10 M
as on 05-12-2024
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 14.55 Cr
as on 05-12-2024
- Satisfied Charges ₹ 1.15 Cr
as on 05-12-2024
- Revenue %
(FY 2021)
- Profit 86.28%
(FY 2021)
- Ebitda 96.68%
(FY 2021)
- Net Worth
- Total Assets -1.83%
(FY 2021)
About Sunsai Laboratories
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹14.55 Cr. The company has closed loans amounting to ₹1.15 Cr, as per Ministry of Corporate Affairs (MCA) records.
Nishit Kadakia and Prakash Kadakia serve as directors at the Company.
- CIN/LLPIN
U24233TG2015PTC100312
- Company No.
100312
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Aug 2015
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Medak, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sunsai Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nishit Kadakia  | Additional Director | 06-Feb-2019 | Current |
| Prakash Kadakia | Additional Director | 06-Feb-2019 | Current |
Financial Performance of Sunsai Laboratories.
Sunsai Laboratories Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 86.28% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth | |||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sunsai Laboratories?
In 2019, Sunsai Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shruti Drugs Private LimitedActive 30 years 5 monthsNishit Kadakia and Prakash Kadakia are mutual person
- Redlabs Chemicals Private LimitedActive 8 years 2 months
Nishit Kadakia and Prakash Kadakia are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 19 Oct 2022 | ₹14.55 Cr | Open |
Others Creation Date: 14 Apr 2017 | ₹1.15 Cr | Satisfied |
How Many Employees Work at Sunsai Laboratories?
Unlock and access historical data on people associated with Sunsai Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sunsai Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sunsai Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
